For Investors

Press Releases

Lifeward to Report Second Quarter 2026 Financial Results on August 14, 2026

08/07/26

HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the Company

Read More
Read More

Lifeward Launches Pilot Program with Ottobock Care to Expand National Access to ReWalk® Personal Exoskeleton

08/05/26

Ottobock Care, one of the leading mobility technology   patient care organizations in the U.S.,   bring s   extensive clinical expertise and patient care infrastructure A dvances Lifeward’s strategy to broaden ReWalk access through capital-efficient channel partner model intended to accelerate

Read More
Read More

Lifeward Secures Growth Capital to Accelerate Commercial Expansion with Up to $11.2 Million in Strategic Financing

07/07/26

Initial $5.6 million provides immediate capital to accelerate commercialization of Lifeward's restorative healthcare platform; additional $5.6 million available upon achievement of defined commercial and financial milestones HUDSON, Mass. and YOKNEAM ILLIT, Israel, July 07, 2026 (GLOBE NEWSWIRE) --

Read More
Read More

Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform

05/19/26

Veteran physician, medical affairs and clinical research leader   brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience, mobility technologies, and metabolic disease Promotion reflects Lifeward’s continued investment in clinical innovation, evidence generation,

Read More
Read More

Lifeward Reports First Quarter 2026 Financial Results

05/15/26

Oramed  strategic transaction   successfully closed and $10 million   financing received Oratech acquisition brings $6. 5 million in cash and promising   Protein Oral Delivery ™ biomed technology, with lead asset ORMD-0801 oral insulin set to commence Phase 2 study Acquired upper body exoskeleton

Read More
Read More

Lifeward to Report First Quarter 2026 Financial Results on May 15, 2026

05/11/26

HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the Company

Read More
Read More

Lifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton

05/04/26

Global data since 2013 show just 3% lifetime fracture prevalence, declining to 0.3% over the past six y ears Zero fractures reported across 97 German users since 2018, spanning broad patient profiles and bone health conditions Findings reinforce safety profile and support expanded adoption of

Read More
Read More

Lifeward Successfully Closes on Strategic Partnership with Oramed

03/25/26

HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that it has closed on

Read More
Read More

Lifeward Reports Fourth Quarter and Full Year 2025 Financial Results

03/18/26

Advancing t ransformation into a d iversified b iomedical i nnovation c ompany with a c lear p ath to c ash f low p ositiv e Oramed s trategic t ransaction r eceives   s hareholder a pproval;   Lifeward g ain s   n ew o ral p rotein d elivery t echnology p latform Lifeward a lready e xecuting n ew

Read More
Read More

Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company

03/13/26

Position s Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed’s POD™ oral delivery technology expands Lifeward into biotech markets while Oramed funds the platform’s clinical development Provides Lifeward access to up to $47 million of

Read More
Read More

Lifeward Regains Compliance with Nasdaq Minimum Bid Price Requirement

03/11/26

HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced it has received a

Read More
Read More

Lifeward to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026

03/10/26

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company

Read More
Read More
Displaying 1 - 12 of 352